In this study we evaluated the effects of the CB1/CB2 cannabinoid receptor agonist CP55, 940 (CP) 
Introduction

Asthma is a chronic inflammatory disease of the airways characterized by eosinophilia, increased vascular permeability in the bronchial mucosa, mucus hypersecretion and airway hyperresponsiveness. The prevalence of asthma has increased dramatically over the past decades and currently affects about 10% of the population in developed countries [1]. Although there is a general consensus about the use of corticosteroids and bronchodilators as main therapeutic measures for the prevention and management of asthma, the identification and development of promising new substances with anti-asthmatic effects that can flank and co-operate with the above drugs is a fertile field for basic and clinical research because of its primary medical interest.
Recently, claims have been made for the beneficial effects of cannabis and cannabinoids, the active components of Cannabis sativa. This plant has a long history as a drug source. Over the centuries, it has been used for many purposes, including the treatment of asthma [2] . Early studies have indicated that cannabinoids have bronchodilatory effects in asthmatic patients when administered either orally or by aerosol [3, 4] . Moreover, cannabinoids also have anti-inflammatory effects [5, 6] and have been recently used as novel therapeutic tools in immune-mediated diseases, such as multiple sclerosis [7] , rheumatoid arthritis [8] and diabetes [9] . [10] .
In murine models of ovalbumin-induced allergic airway response, cannabinoids have shown inhibitory effects on T cell cytokine expression, serum IgE levels and mucus overproduction
Cannabinoids bind to specific G-protein-coupled receptors [11, 12] . To date, two cannabinoid receptors, termed CB1 and CB2, have been isolated and cloned. CB1 is predominantly expressed in the central nervous system and has been also detected in the testis, spleen cells and leukocytes [13, 14] . CB2, mainly expressed by cells of the immune system, is also present on microglial cells [12] [13] [14] .
A recent report has suggested that the endocannabinoid system could play a role in lung function. In fact, anandamide, an endocannabinoid agonist, is produced in lung tissue and CB1 receptors are expressed on axon terminals of nerve fibres in rat bronchiolar smooth muscle [15] . In a rodent model of bronchial hyper-responsiveness, anandamide exerted opposite effects: it strongly inhibited bronchospasm and cough evoked by capsaicin, whereas it caused bronchospasm when the constricting tone exerted by the vagus nerve was removed [15] . Therefore [16, 17] . We used the cannabinoid receptor agonist CP55, 940 (CP) [18] , and we tested the ability of the specific CB2 receptor antagonist SR144528 (SR) [19] and CB1 receptor antagonist AM251 (AM) [20] to interfere with the effects of CP.
, the activation of CB1 receptors by locally released anandamide could participate in the control of bronchial contractility. The existence of an intrinsic endocannabinoid-mediated control of airway function may open new perspectives for the development of new antitussive and anti-asthmatic agents. Recently, selective agonists and antagonists for the CB1 and CB2 receptors have been made available, thus offering a suitable pharmacological tool to better understand the role of the cannabinoid receptors in lung physiopathology. The aim of this study was to investigate the role of CB1 and CB2 receptors on allergic asthmalike reaction in a well-established in vivo model of ovalbumin (OV)-sensitized guinea pigs
Materials and methods
Animals
Male adult albino guinea pigs were quarantined for 7 days at 22-24°C on a 12 hrs light, 12 hrs dark cycle before use. The experimental protocol was basically the same used previously for similar purposes [16, 17] [19, 20] .
Evaluation of respiratory activity
The guinea pigs of all the groups were placed in a whole body respiratory chamber, as described previously [16, 17] 
Results
CP reduces OV-induced respiratory abnormalities
The values of the respiratory parameters assayed are reported in Fig. 1A (Fig. 2) , the lung parenchyma of naive guinea pigs (group 1) had a normal appearance: intrapulmonary bronchi showed open lumina and respiratory air spaces were mostly small-sized (Fig. 2A) 
. Conversely, the lungs from the OV-challenged guinea pigs (group 2) mostly showed a reduction of the lumen of intrapulmonary bronchi, with long mucosal folds
Fig. 2 Representative light micrographs of lung tissue from naive guinea pigs given OV aerosol (A; group 1), sensitized guinea pigs challenged with OV aerosol (B; group 2), sensitized guinea pigs treated with the CB1/CB2 receptor agonist CP before OV challenge (C; group 3), sensitized guinea pigs pre-treated with CP in combination with the CB1 receptor antagonist SR (D; group 4), the CB2 receptor antagonist AM (E; group 5) or both (F; group 6). Compared with the animals of group 1, those of group 2 show reduction of bronchiolar lumen and dilation of the respiratory air spaces. These alterations are not evident in the CP-treated guinea pigs of group 3, but persist in the animals given SR, AM or both 3 hours before CP (groups 4, 5 and 6, respectively). Haematoxylin and eosin. Bars = 100 m.
expanding into the lumen and markedly dilated respiratory air spaces (Fig. 2B) . In the CP-treated guinea pigs (group 3), the histological lung abnormalities were nearly abrogated. In fact, the intrapulmonary bronchi usually showed no appreciable signs of constriction, and most respiratory air spaces were not dilated (Fig. 2C) . (Fig. 2D-F) .
In the guinea pigs pre-treated with SR, AM or both the antagonists before CP (groups 4, 5 and 6), the histological features were quite similar to those of the OV-challenged animals
The visual observations were objectified by morphometric analysis (Fig. 3A and Fig. 4A and B) . In the CP-treated guinea pigs (group 3), the mast cell staining intensity was markedly increased in respect to the OV-challenged animals (group 2), attaining values similar to those of the controls (Fig. 4C) . (Fig. 4D-F) . Computer-aided densitometry confirmed the visual observations (Fig. 4G) 
B). Compared with the naive guinea pigs of group 1, the OV-challenged guinea pigs (group 2) showed a significant increase in the mean surface area of alveolar air spaces and a significant decrease in the mean surface area of bronchiolar lumina. In the CP-treated guinea pigs (group 3) the mean surface area of alveolar air spaces nearly returned to the control values and the mean surface area of bronchiolar lumina was significantly increased compared to the OV-challenged animals. With respect to the CP-treated group, pre-treatment with SR, or AM, or both the antagonists significantly prevented the CP-induced reduction of the mean surface area of alveolar air spaces but had little effects on the mean surface area of bronchiolar lumina.
Fig. 3 Surface area of alveolar air spaces (A) and small-sized bronchial lumina (B) in the lungs of guinea pigs from the different experimental groups. Compared to the OV-challenged, untreated animals (group 2) in the guinea pigs treated with the CB1/CB2 receptor agonist CP (group 3) the mean surface area of alveolar air spaces nearly returned to the control values and the mean surface area of bronchiolar lumina was significantly increased. With respect to the CP-treated group, pre-treatment of the sensitized guinea pigs with the CB1 receptor antagonist SR (SR+CP, group 4) or the CB2 receptor antagonist AM (AM+CP, group 5) or both (SR+AM+CP, group 6) before CP administration significantly prevented the reduction of the mean surface area of alveolar air spaces but not the increase of the mean surface area of bronchiolar lumina. Significance of differences (one-way
CP reduces OV-induced mast cell granule release
Lung mast cells from the OV-challenged guinea pigs (group 2) underwent a marked decrease in Astra blue staining intensity, which depends on secretion granule content, as compared with those from the naive controls (group 1), thus indicating that granule discharge has occurred (
As compared with the animals of group 3, mast cell staining intensity was slightly decreased in the guinea pigs pre-treated with SR (group 4), or AM (group 5), or both the antagonists (group 6)
. Compared with the naive controls (group 1), the optical density of Astra blue-stained mast cells was significantly reduced in OV-challenged guinea pigs (group 2), but not in the CP-treated guinea pigs (group 3). As compared with the latter animals, mast cell optical density was decreased, but not significantly, in the guinea pigs pre-treated with SR (group 4), whereas the decrease reached statistical significance in the guinea pigs pre-treated with AM (group 5) and in those pre-treated with both the antagonists (group 6).
CP reduces OV-induced lung leukocyte infiltration
Myeloperoxidase activity (Fig. 5) 
CP reduces OV-induced 8-OHdG production
Tissue levels of 8-OHdG (Fig. 7) 
CP reduces OV-induced release of TNF␣ and PGD 2 in BAL fluid
The inflammatory cytokine TNF␣ (Fig. 8A) and PGD2 (Fig. 8B 
CP reduces OV-induced increase of cAMP levels
As CB1 and CB2 receptors are G protein-associated, cyclic nucleotide-operating receptors, we evaluated the levels of cAMP and cGMP in lung tissue extracts. Cyclic AMP levels (Fig. 9A) in lung tissue were similar in the samples from the OV-challenged animals (group 2) and the controls (group 1). In the CP-treated guinea pigs (group 3) , the values of cAMP were significantly lower than in the previous groups, while in the animals pre-treated with the antagonists, given alone or together (groups [4] [5] [6] , the cAMP values were similar to those of the control (group 1) and OV-challenged animals (group 2). On the other hand, cGMP levels did not change among the experimental groups (Fig. 9B) . with CP nor pre-treatment with the noted antagonists resulted in any modification in the receptor protein expression (Fig. 10) . [27] , suggesting a neural control on mast cell function [28] [29] [30] . The influence between nerves and mast cells is reciprocal: neurons change their firing rate upon mast cell degranulation [29] , and mast cells may activate upon neural stimulation [30] . A feedback has been also suggested for mast cells and non-myelinated sensory C-fibres [31] , the major vagal afferents to the airways [32] , which have been involved in lung vascular and bronchial changes caused by allergy [33] and by inhalation of chemical irritants and air pollutants [34] . Our data suggest that CP may directly reduce the activation of mast cells via their CB2 receptors, as we previously demonstrated in vitro [6] , and also indirectly via the CB1 receptors located on nerve endings distributing to the bronchial smooth muscle coat [15] .
Discussion
The present study also shows that CB2 receptors are likely involved in the decrease in myeloperoxidase (MPO) activity and eMBP-positive eosinophils induced by CP. This indicates that CP exerts its anti-inflammatory activity mainly through CB2 receptors, in keeping with our previous results [6, 35] effects [10, 36] . Among the latter ones, the indirect, antioxidant effects of cannabinoids may turn out very useful in asthma, considering that increased levels of oxygen-derived free radicals and high-energy oxidants produced by inflammatory and epithelial cells in the airways are deemed important pathogenic mediators of asthma [37, 38] .
In 
